Use this tool to search the directory.
Victoria, Australia, leads the Asia Pacific region in high quality biotechnology research and development infrastructure, skills and know-how.
Victoria is home to a comprehensive array of facilities and platform technologies, including unique capabilities such as the Australian Synchrotron, the Victorian Cancer Biobank, BioGrid Australia, and the Victorian Life Sciences Computation Initiative.
Launched in 2010, the Victorian Platform Technologies Network connects Victoria’s extensive platform technologies and is a central access point for research and industry.
Victoria is Australia’s largest biotechnology sector. Comprising more than 135 biotechnology companies, 13 major medical research institutes, eleven teaching hospitals and nine universities, Victoria is an innovative hub for world-recognised bioscience.Melbourne, Victoria’s capital city, is home to 50% of the top 20 biotechnology companies listed on the Australian Stock Exchange and almost 65% of Australia’s top biotechnology companies by market capitalisation.The Victorian State Government and the biotechnology industry are together working towards building and enhancing: a competitive business environment, growing sustainable companies, expanding international connections and attracting ongoing investment.
3rd September 2010. The Board of Research Australia is delighted to announce the appointment of Dr Christine Bennett as Chairman of Research Australia. Dr Bennett is Chief Medical Officer and Director Health Care Leadership with Bupa Australia.
A three-year-old girl from Gippsland has become the recipient of the 2000th cochlear implant at The Royal Victorian Eye and Ear Hospital.
Phosphagenics Limited has exercised its option to licence the Calzada Limited patented compound, AOD9604, for use as a cosmeceutical product aimed at reducing the appearance of cellulite and subcutaneous fat.
30 August 2010. In the last 12 months, 23 biotech's went to IPO around the world - one from Australia. This update, sourced from Inside Bio summarises the companies, where they are from and how much they raised.
Friday, 27 August 2010 — A big win for Victorian biotechnology last night at the 10th Entrepreneur Of The Year Southern Region Awards . Richard Treagus, CEO of Acrux, won the 'Listed' category. Richard will now progress into the Australian final in November.
Acrux (ASX: ACR) today announced a maiden profit of $46.6 million, resulting in diluted earnings of 28.7 cents per share
Thomson Reuters today announces that the Medical Research Commercialisation Fund (MRCF) has chosen Thomson Pharma® to serve the key commercialisation and business development needs of its 27 members.
24 August, 2010. Melbourne. Phosphagenics appoints 3 new non-executive directors to boost its commercial transformation. Stuart James, Sandra Webb and Don Clarke.
Today at the XIIth International Congress of Parasitology (ICOPA XII) Andy Waters, head of the European Virtual Institute for Malaria Research (EVIMalaR) will tell us how a global network of scientists will tackle the biggest human parasite problem; malaria.